Clinical trials
Advanced Solid Cancer clinical trials
Below are recruiting advanced solid cancer clinical trials, each written for real people, not researchers. We’re tracking 1,329 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06804824RecruitingPhase 1
Testing a new drug for advanced solid tumors with certain gene changes
This study tests an experimental drug called VVD-159642 in people with advanced solid tumors that have specific genetic changes (RAS or EGFR alterations, or HER2 overexpression). The goal is to see if the drug is safe and tolerable.
Grand Rapids, MichiganAges 18 years+ - NCT06833008RecruitingPhase 1/Phase 2
Study of new medicine IPN01195 for advanced solid tumors
This study tests a new medicine called IPN01195 for adults with advanced solid tumors that have a specific genetic change (MAPK pathway). It aims to see if the drug is safe and works against these cancers when other treatments are no longer working.
Grand Rapids, MichiganAges 18 years+ - NCT06589596RecruitingPhase 1
Study of BGB-58067 for advanced solid tumors
This trial tests an experimental drug called BGB-58067, either alone or with other cancer treatments, for people with advanced solid tumors that have stopped responding to standard therapy. It may be an option if you have a specific genetic change (loss of MTAP) in your tumor.
Los Angeles, CaliforniaAges 18 years+ - NCT06514651RecruitingPhase 1
MAQ-001 for advanced solid tumors after PD-1/PD-L1 therapy
This study tests a new experimental drug called MAQ-001 in people with advanced solid tumors or lymphomas that have already been treated with a PD-1/PD-L1 checkpoint inhibitor. The goal is to see if MAQ-001 can shrink or control the cancer when other treatments are no longer working.
LyonAges 18 years+ - NCT05684965RecruitingPhase 1/Phase 2
Study drug for advanced solid cancers after standard treatments
This Phase 1/2 trial tests XTX301, a study treatment, in people with advanced solid tumors (cancers) that have already been treated and are not controlled by standard options. It may help if your cancer matches one of the study groups and you meet safety and test-tissue requirements.
Sacramento, CaliforniaAges 18 years+ - NCT06764836RecruitingPhase 1
IMM2510 + IMM27M for advanced solid tumors
This study tests a combination of two immune-based drugs, IMM2510 and IMM27M, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink or slow the growth of cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06532565RecruitingPhase 1
Study of GS-2121 alone or with other drugs for advanced solid tumors
This trial tests a new drug, GS-2121, given alone or with other therapies, for adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and effective.
Palo Alto, CaliforniaAges 18 years+ - NCT06102824RecruitingPhase 2
Organoid-guided treatment for advanced breast cancer
This trial tests whether using a miniature version of your tumor grown in a lab can help choose the best treatment for advanced breast cancer. It compares this personalized approach to standard care.
Guangzhou, GuangdongAges 18–80 - NCT05881525RecruitingPhase 1
Testing NY-ESO-1 T-cell therapy for advanced solid tumors
This Phase 1 study tests a personalized immune therapy made from T cells to treat advanced solid cancers that carry a marker called NY-ESO-1. You may be able to join if your tumor shows the right NY-ESO-1 level and your body and lab tests can safely handle treatment.
ChongqingAges 18–70 - NCT07252414RecruitingPhase 1
Study of GenSci143 for advanced solid tumors
This trial tests a new drug, GenSci143, for people with advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has spread or come back and you have no other standard options left.
Zhengzhou, HenanAges 18 years+ - NCT06796699RecruitingPhase 1
GH56 capsule study for MTAP-deleted advanced solid tumors
This study tests an experimental capsule (GH56) for people whose advanced solid tumors have a specific genetic change called MTAP deletion. The goal is to see if the capsule is safe and helps shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06597721RecruitingPhase 1
ADCE-T02 for advanced solid tumors
This trial tests a new drug called ADCE-T02, which is an antibody-drug conjugate designed to target and deliver a chemotherapy payload to cancer cells that have a protein called tissue factor. The study is for people with advanced solid tumors that have not responded to other treatments, and it aims to see if the drug is safe and effective.
Rogers, ArkansasAges 18 years+ - NCT07110883RecruitingPhase 1
Study of SYS6023 for advanced solid tumors
This trial tests a new drug called SYS6023 for people with advanced solid tumors that have not responded to standard treatments. It may be an option if your tumor has a specific protein called HER3 or certain genetic changes.
Harbin, HeilongjiangAges 18 years+ - NCT06819735RecruitingPhase 1/Phase 2
Testing DT-7012 in Advanced Solid Tumors
This trial tests a new drug called DT-7012, given alone or with another immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if DT-7012 can shrink tumors or slow their growth.
Scottsdale, ArizonaAges 18 years+ - NCT05979155RecruitingPhase 1
Study of NWY001 for advanced solid tumors
This study tests a new experimental drug (NWY001) for people with advanced solid tumors that have stopped responding to standard treatments. It is a phase 1 trial, meaning it is early research to find the right dose and check for side effects.
Guangzhou, GuangdongAges 18–75 - NCT06953323RecruitingPhase 1/Phase 2
Study of WJB001 combined therapy for advanced solid tumors
This trial tests a new drug combination for people with advanced solid tumors that are no longer responding to standard treatments. It focuses on patients whose tumors have high levels of a protein called CCNE1, particularly for certain ovarian, fallopian tube, peritoneal, and uterine cancers.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07259889RecruitingPhase 1
CEL001 injection safety study for advanced solid tumors
This trial tests a new injection called CEL001 for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The goal is to see if it is safe and find the right dose.
BeijingAges 18 years+ - NCT07744763RecruitingPhase 1/Phase 2
Study of SYS6041 for advanced solid tumors
This trial tests a new drug called SYS6041 for people with certain advanced cancers that have not responded to standard treatments. It targets a protein called FRα found on some tumor cells, which may help the drug attack the cancer more effectively.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05007782RecruitingPhase 1
Testing a new immune drug for advanced solid tumors
This Phase 1 study tests denikitug (GS-1811) alone or with zimberelimab in adults with advanced solid tumors. It’s looking mainly at safety and how the treatment works in people whose cancer has already been treated—or is not treatable with standard options.
La Jolla, CaliforniaAges 18 years+ - NCT07266285RecruitingPhase 1
Testing BTM-3566 for advanced solid tumors
This trial tests a new drug, BTM-3566, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Houston, TexasAges 18 years+ - NCT06686745RecruitingPhase 1
Study of an experimental drug alone and with combination for advanced solid tumors
This trial tests a new drug called SIM0508, given alone or with another drug (olaparib), in people with advanced ovarian, prostate, breast, or pancreatic cancer. The goal is to see if it is safe and effective.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06682780RecruitingPhase 1/Phase 2
Testing LM-2417 for advanced solid tumors
This trial tests a new drug, LM-2417, for people with advanced solid tumors that have come back or not responded to treatment. The study will see if LM-2417 is safe and effective, possibly as a new option for those who have run out of standard therapies.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06625593RecruitingPhase 1
Study of BG-C137 for advanced solid tumors
This trial tests a new drug called BG-C137 for people with advanced solid tumors that have stopped responding to other treatments. The drug targets a protein called FGFR2b found on some cancer cells, aiming to deliver a therapy directly to the tumor.
Los Angeles, CaliforniaAges 18 years+ - NCT06302426RecruitingPhase 1
Testing INI-4001 for advanced solid tumors
This trial tests a new drug, INI-4001, for people with advanced solid tumors that have spread or can't be removed. It aims to see if the drug is safe and effective.
Albury, New South WalesAges 18 years+
Hear when a new Advanced Solid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid cancer?
- Yes. Clin2 currently lists 1,329 recruiting advanced solid cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.